Skip to content
conflictLOW2026-04-28 13:54 UTC

Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel - citybiz

Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel  citybiz

ORIGINAL SOURCE →via M&A News (GN)
ADVERTISEMENT
⚡ STAY AHEAD

Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.

GET THE SUNDAY BRIEFING →

RELATED · conflict